Selected positions
2022–Present
Chief Scientific Officer
RedHill BioPharma, Ltd.
2020–Present
Board of Directors
EnGeneIC, Ltd.
2013–Present
CEO, Levitt Oncology Associates, Ltd.
Hashmonaim, Israel
2009–2013
Head, Oncology — Global Business Development
Teva Pharmaceuticals Industries, Ltd.
2006–2009
Clinical Oncology Platform Leader, Innovative R&D
Teva Pharmaceuticals Industries, Ltd.
1987–1994
Assistant Professor · Director, Lung Cancer Center
University of Pittsburgh / Pittsburgh Cancer Institute
Selected commercial highlights
2011
Led oncology due diligence — Teva acquisition of Cephalon
Deal value: $6.8 billion
2009
Led licensing deal — OncoGeneX OGX-011 (Custirsen)
Deal value: $430M in upfront and milestone payments
2006
INO-1001 PARP inhibitor development — licensed to Genentech
Deal value: up to $625M
Selected publications
Winthrop KL et al. (incl. Levitt ML). Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial. Open Forum Infectious Diseases, 2022.
Horn L, Bernardo P, Levitt M et al. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiotherapy for limited stage small cell cancer (E2596). J Thorac Oncol, 2009.
Kundel Y, Levitt ML et al. Adjuvant radiotherapy for thymic epithelial tumor. Am J Clin Oncol, 2007.
Levitt ML et al. Phase I Study of Gemcitabine Given Weekly as a Short Infusion for Non-Small Cell Lung Cancer. Lung Cancer, 2004.
Lokshin A and Levitt ML. Effect of Suramin on Squamous Differentiation and Apoptosis in Non-Small Cell Lung Cancer. J Cell Biochem, 1996.
Nair S, Mayotte J and Levitt ML. Induction of Squamous Differentiation by Interferon-β in a Human Non-Small Cell Lung Cancer Cell Line. J Natl Cancer Inst, 1994.
Takahashi T, (incl. Levitt ML). p53: A Frequent Target for Genetic Abnormalities in Lung Cancer. Science, 1989.
+ 30 additional peer-reviewed publications. Full list available in downloadable CV.
Patents
Tenne G, Levitt ML, Karapetian A. Method For The Early Diagnosis Of Cancer. Era-Massis. US20030044881, 2003; US7449340, 2008.
Fathi R, Levitt M et al. Use of WX-UK1 and its prodrug WX671 for treatment of inflammatory diseases. RedHill Provisional #62/535,376, 2017.